HealthDay on MSN4d
GLP-1 RA Use Linked to Reduced Cirrhosis Risk in MASLD, Diabetes
For patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1 ...
Daily6d
Cleveland Clinic Study Identifies Key Factors Influencing Long-Term Weight Loss with GLP-1 RA Medications
A Cleveland Clinic study identified key factors that can impact the long-term weight loss of patients with obesity who were ...
Medscape5d
Longer Acting GLP-1 Receptor Agonists and the Potential for Improved Cardiovascular Outcomes
[18] There was no significant difference in weight change between any of the albiglutide dosings, with average weightloss being -1.1 to -1.7 kg ... with current GLP1-RA in terms of glycemic ...
thecardiologyadvisor.com3d
GLP-1 Receptor Agonists vs SGLT2 Inhibitors and Kidney, Heart Outcomes in T2D
Follow-up data was collected through December 2021. Clinical trials are needed to directly compare SGLT2i and GLP-1 RA in people with and without T2D over longer follow-up durations. Covariates for ...
Women's Health on MSN2d
The Ozempic Side Effect That No One’s Talking About
A new study finds that weight loss drugs Like Ozempic could trigger bone loss. Doctors explain why, and how to protect ...